Navigation Links
Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
Date:6/8/2009

s study are being treated at the NCI and at top cancer centers throughout the United States. The NCI is serving as coordinating center for the study, which includes the initiation and training of the new clinical trial centers for this important trial. Plans under the CRADA include continuing patient enrollments and completing the clinical testing of PHP as treatment for a number of life threatening liver diseases.

The Phase III Study

The Phase III study is testing Delcath's PHP(TM) System for the regional delivery of melphalan to the liver to treat patients with metastatic cutaneous and ocular melanoma who have unresectable tumors in the liver. The Delcath System is designed to deliver significantly higher doses of anti-cancer drugs to a patient's liver while preventing entry of the drugs to the rest of the patient's circulation. This isolation limits toxicities that result from systemic chemotherapy treatments.

Patients in the Phase III trial initially are randomized into one of two treatment arms, including immediate treatment with melphalan via the Delcath System or treatment with best alternative care. The study is designed to evaluate the duration of tumor response in each of the two study arms. Following guidelines established by U.S. Food and Drug Administration under a Special Protocol Assessment (SPA), when disease progresses in patients enrolled in the best alternative care arm of the trial, they are permitted to "cross over" and receive treatment with the Delcath System.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer drugs to the liver while preventing these high doses of drug from entering the patient's b
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
2. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
5. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
6. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
7. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer
10. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
11. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... 2014  BC Technical, the largest nationwide, non-OEM provider ... Inc., a leading provider of Siemens Nuclear Medicine and ... naming BC Technical as the authorized provider of service ... and BC Technical announced today that the two companies ... as the service and systems provider for MiE,s camera ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... 2011 ChromaDex Corporation (OTCBB: CDXC), an innovative ... and ingredients to the dietary supplement, food & ... results for the second quarter of 2011. On ... U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex ...
... NEW YORK, Aug. 11, 2011 Citeline, an Informa ... pharmaceutical clinical trials recently reviewed the findings from the ... July 16-21, 2011, noting that while pharma continues to ... ahead in terms of biomarkers and early warning for ...
Cached Medicine Technology:ChromaDex Announces Financial Results for Second Quarter 2011 2ChromaDex Announces Financial Results for Second Quarter 2011 3ChromaDex Announces Financial Results for Second Quarter 2011 4Global Standardization for Alzheimer's Biomarkers Moves a Major Step Closer to Reality 2
(Date:7/13/2014)... 13, 2014 The report “Micronutrient ... Iron), Form (Chelated & Non Chelated), Application Mode ... Global Trends and Forecast to 2018” defines and ... analysis and forecasting of the global value and ... driving and restraining factors for the global agriculture ...
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... Athletes with a certain genetic make-up are prone ... research presented today at the American Orthopaedic Society for ... marks the first of its kind investigating a genetic ... that occur after a head injury. , “We ... (GT)n genotype were four times more likely to have ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... 13, 2014 A decreased ability to identify ... and Alzheimer,s disease, while examinations of the eye ... associated with Alzheimer,s, in the brain, according to ... at the Alzheimer,s Association International Conference 2014 (AAIC ... studies, the decreased ability to identify odors was ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... biomaterial, developed at the New Jersey Center for Biomaterials ... bench to field testing in record time. This achievement, ... is the enabling technology behind a coronary stent undergoing ... , Stents are tiny tubes inserted into diseased arteries ...
... of neurotransmitter dopamine , , THURSDAY, Oct. 18 (HealthDay ... the brain that may explain why some people ... difficult situations. , While the research was done ... better treatments for chronic stress, depression and the ...
... Minn. -- Mayo Clinic has clarified the methods of ... blood vessel disease of the brain and spinal cord ... nervous system vasculitis (PCNSV) can best be identified through ... the cerebral arteries), brain biopsy and other laboratory studies. ...
... Oct. 18 The U.S. House,Judiciary Committee Antitrust ... 971,the Community Pharmacy Fairness Act of 2007. The ... that would allow independent pharmacies to,compete fairly and ... (PBMs). In response Bruce Roberts, RPh, National Community,Pharmacists ...
... ReBuilder,Medical Technologies, Inc. (Pink Sheets: RBRM), an ... device inventor David B.,Phillips, Ph.D., today announced ... facilitation. (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO ) ... are outsourcing customer service to,overseas facilities, the ...
... Preventive Medical Exams; New Women,s Health ... Texas, Oct. 18 Signaling the next phase ... residential,community under development in McKinney, the Cooper Clinic ... "Father of aerobics" Dr. Kenneth Cooper, who,founded Cooper ...
Cached Medicine News:Health News:Rutgers biomaterial debuts in clinical trials of new stent 2Health News:Rutgers biomaterial debuts in clinical trials of new stent 3Health News:Vulnerability to Stress Linked to Brain Molecule 2Health News:Vulnerability to Stress Linked to Brain Molecule 3Health News:Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord 2Health News:Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord 3Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 2Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 3Health News:Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney 2Health News:Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: